Heart failure & cardiomyopathies
Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2
Study context
- Population
- Patients with symptomatic heart failure (HF) and moderate to severe functional mitral regurgitation333 with prior HF hospitalization
- Comparison
- Mitral transcatheter edge-to-edge repair (M-TEER) vs control
- Primary endpoint
- Hospitalization rates
- Follow-up
- 24 months
Methodological detailsprespecified analyses
- Prespecified analyses
Primary result
As reported in the abstract
Hospitalization outcomes
M-TEER vs ControlEstimate (95% CI)P value
Time to first CV death or HF hospitalization
HR 0.65(0.49–0.85)
P = 0.002Recurrent CV hospitalizations (rate ratio)
RR 0.75(0.57–0.99)
P = 0.046Recurrent CV hospitalizations and all-cause mortality
RR 0.74(0.57–0.95)
P = 0.017Recurrent CV death and CV hospitalizations
RR 0.76(0.58–0.99)
P = 0.040Recurrent all-cause hospitalizations
RR 0.82(0.63–1.07)
P = 0.15Further findings
Follow-up time lost due to death or HF hospitalization
Total days lost M-TEER 1,067 · Control 1,776
- Follow-up time lost due to death or HF hospitalization: P < 0.0001 for both
NYHA functional class · 30 days, 6, 12 and 24 months
- Better NYHA class with M-TEER
- P < 0.0001
Prior HF hospitalization (subgroup, n = 333) · 24 months
- Prior HF hospitalization associated with worse outcomes and greater M-TEER benefit on recurrent HF hospitalizations and cardiovascular (CV) death
- P for interaction = 0.03
- Greater M-TEER benefit on recurrent HF hospitalizations
- P for interaction = 0.06
Original publication
Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2. J Am Coll Cardiol. Published 31 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →